Results 221 to 230 of about 205,750 (304)

Benchmarked Colorectal Cancer Outcomes in a Metropolitan Hospital: A 5‐Year Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
In metastatic disease, patients with lung‐only metastasis had the best 5‐year survival at 46.0% and curative‐intent approaches can dramatically improve survival. ABSTRACT Introduction Colorectal cancer (CRC) remains a major contributor to cancer‐related mortality worldwide, with survival influenced by many prognostic factors.
Jialin Du, Vincent Wang, Basil D'Souza, Russell Hodgson   +3 more
wiley   +1 more source

Timely Delivery of Care and the Optimal Care Pathway for People With Colorectal Cancer: A Scoping Review

Asia-Pacific Journal of Clinical Oncology, EarlyView.
The “Optimal care pathway for people with colorectal cancer” is a framework designed to support clinicians delivering high‐quality, timely care to patients; however, it is unknown whether this has affected outcomes across Australia. The variable results in this review suggest that this guideline is yet to be integrated nationally. ABSTRACT The “Optimal
Elliott Benjamin Fox, Dennis Perez Castillo, Nathan Bain, Amy Brown   +3 more
wiley   +1 more source

Surgical decision-making after neoadjuvant chemotherapy in pancreatic ductal adenocarcinoma. [PDF]

Ann Surg Treat Res
Lee H.
europepmc   +1 more source

Top 5 Advances in the Last 50 Years: Malignant Gastric and Esophageal Surgery

World Journal of Surgery, EarlyView.
Luís Santos Castro, Lorenzo Ferri
wiley   +1 more source

Management of Advanced Prostate Cancer in the Asia‐Pacific Region: Summary of the Asia‐Pacific Advanced Prostate Cancer Symposium 2025

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Summary of the Asia Pacific Advanced Prostate Cancer Symposium 2025, showing disciplines and diversity of participants, discussion topics (high‐risk localized/locally advanced prostate cancer; PSA persistence and recurrence; radioligand therapy; genetics and genomics; bone protection and other aspects of supportive care), key themes, and high‐level ...
Edmund Chiong, Renu Eapen, Nicholas Buchan, Kenneth Chen, Lukman Hakim, Agus Rizal Hamid, Jae‐Young Joung, Ravindran Kanesvaran, Makarand Khochikar, Jason Letran, Bannakij Lojanapiwat, Indranil Mallick, Chi Fai Ng, Pei Ing Ngam, Teng Aik Ong, Jacob Pang, Darren M. C. Poon, Natasha Roberts, Marniza Saad, Shinichi Sakamoto, Jeremy Tey, Sue Ping Thang, Poh Choo Toh, Levent Türkeri, Nguyễn Tuấn Vinh, Alvin Wong, Yao Zhu, ANZUP Cancer Trials Group, Ian D. Davis   +28 more
wiley   +1 more source

Adjuvant capecitabine in women with triple-negative breast cancer with residual disease after carboplatin-containing neoadjuvant chemotherapy. [PDF]

Breast Cancer Res Treat
Tavares GM, Ramalho SOB, da Silva LR, Telles GD, de Paiva Silva GR, Torresan RZ, Derchain SFM.   +6 more
europepmc   +1 more source

Pancreatic Cancer—Advances in the Last 50 Years

World Journal of Surgery, EarlyView.
S. George Barreto, Anirban Maitra, Eileen M. O'Reilly, Dushyant Sahani, Richard Zheng, Charles J. Yeo   +5 more
wiley   +1 more source

Outcomes for Patients With Micro‐Invasive or Small HER2+ Breast Cancer in Northern Sydney Local Health District

Asia-Pacific Journal of Clinical Oncology, EarlyView.
This retrospective study of patients with small, node‐negative HER2+ breast cancer found favorable 5‐year invasive disease‐free survival rates—93% for pT1mic/a disease and 100% for pT1b disease. Trastuzumab was administered to 66% of patients and was associated with larger tumor size and higher histologic grade.
Yuanyuan Xue, Katrina Moore, Tricia Saurine, David Chan, Lina Pugliano, Connie Diakos   +5 more
wiley   +1 more source

Locoregional control of downstaged breast-conserving surgery after neoadjuvant chemotherapy: A propensity-matched study in Chinese patients. [PDF]

Breast
Zhang D, Feng Q, Peng M, Zhu L, Chen K, Li S.   +5 more
europepmc   +1 more source

Clinical Outcomes of the POPCORN Study: Pharmacodynamics of Pre‐Operative PD1 CheckpOint Blockade and Receptor Activator of NF‐κB Ligand (RANKL) Inhibition in Non‐Small Cell Lung Cancer (NSCLC)—A Phase 1B/2 Trial

Asia-Pacific Journal of Clinical Oncology, EarlyView.
Expanding on the growing evidence for neoadjuvant immunotherapy in resectable non‐small cell lung cancer, this study explored neoadjuvant nivolumab ± denosumab. Two of the 10 treated patients achieved a pathological complete response. CD8 T‐cell infiltration correlated with pathological response, warranting ongoing translational research to understand ...
Elizabeth Ahern, Cassie Turner, Rishendran Naidoo, David Godbolt, Amy Ives, Kirsten Popplewell, Zarnie Lwin, Sally Pearson, Kimberley Nelson, Jason Madore, William C Dougall, Brett G. M. Hughes   +11 more
wiley   +1 more source